Alzinova: Q4 report, Right on track - Redeye

Redeye provides a research update on Alzinova following the company’s Q4 report published earlier today and recent clinical progress with lead candidate ALZ-101. We make some slight adjustments to our overall estimates following a revision of our model. However, we reiterate our previous fair value range (SEK1 – SEK20) with a base case valuation of SEK10 as we continue to have a positive outlook on the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/883689/alzinova-q4-report-right-on-track?utm_source=finwire&utm_medium=RSS